Gigaohm Biological (Aug 14)
Two great quotes by Walter:
"I would rather have Questions that cannot be answered rather than answers that cannot be questioned" "Do everything that helps and nothing that hurts"
Another cracking show. Walter and Johnathan are starting to connect all the dots.CD147 or Basigin is a novel receptor on red blood cells and augments NF-κB -dependent inflammation in monocytes (= a type of white blood cell called leukocytes). Not only ACE 2 but also CD147 helps the virus enter the cell Recent studies suggests CD147 as SARS-CoV-2 entry receptor of platelets and megakaryocytes, leading to hyperactivation and thrombosis. CD147 plays an important role in human immunodeficiency virus type 1, hepatitis C virus, hepatitis B virus, Kaposi’s sarcoma-associated herpesvirus, and severe acute respiratory syndrome coronavirus infections. CD147 (Basigin) has been shown to be an essential receptor on red blood cells for the human malaria parasite, Plasmodium falciparum. Does this explain why HCQ might be effective?
Walter Chesnut LIVE : Gigaohm Biological High Resistance Low Noise Information Brief (2:15)
Rough Running Order
16:00 Jessica and spike reaction on hemoglobin
17:00 Walter Chestnut interview
24:00 CD147 and blood cancers
27:00 CD147 and Diabetes
28:00 Cat disease and CD147
35:00 Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2
42:00 Antiphospholipid Syndrome ..a mechanism for Recurrent Thrombosis?
45:00 Waldenström macroglobulinemia
01:18 This to shall pass?
01:20 Letter to the editor
01:22 Injection techniques
01:24 End of interview with Walter
01:25 Jessica’s sub stack post
01:26 Monocyte CD147
01:32 They changed the way we think about the immune system:
Antibodies provide no corelate of immunity pic.twitter.com/gSmd9E3c1i
— The Tishbite (@Tishbite_redux) August 14, 2022
01:39 Antibodies do clean-up they come last
01.42 No corelate of protection. Antibodies do not equal immunity
01.47 Deepak fraud
01:50 Bill Gates carbon zero
01:54 The elite think they are Beekeepers
01:56 Albright challenged
02:00 What have we learned?